LUV.png
Acquisition Has Love Pharma’s Naltrexone on NIH Shortlist to Address Unmet Medical Need—Treatment for Long Covid
03 nov. 2022 08h45 HE | Love Pharma Inc.
NEW YORK, NY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health and sexual wellness company, has been explicit about its plans to develop a...
American Society of
American Society of Echocardiography Invests in Joint Research Initiative to Help Patients Suffering from Wide-Reaching Form of Heart Failure
29 sept. 2022 09h30 HE | American Society of Echocardiography
Durham, NC, Sept. 29, 2022 (GLOBE NEWSWIRE) -- The American Society of Echocardiography (ASE) is targeting its research funding over the next five years to help solve some of the mysteries around...
Straits Research Pvt Ltd
CRISPR Gene Editing Market Size is projected to reach USD 14.80 Billion by 2030, growing at a CAGR of 29.80%: Straits Research
01 août 2022 12h40 HE | Straits Research
New York, United States, Aug. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Gene Editing, also called genome editing, modifies an organism's DNA. This method replaces, adds, or removes genetic material from...
South Texans can par
South Texans can participate in massive, national health program to change the future of healthcare
25 juil. 2022 08h30 HE | BioBridge Global
SAN ANTONIO, July 25, 2022 (GLOBE NEWSWIRE) -- South Texas Blood & Tissue has partnered with the National Institutes of Health’s All of Us Research Program, to recruit and engage participants in...
Reveal's New Manganese-Based MRI Contrast Agent Advances Safer Patient Care
New Gadolinium-Free MRI Contrast Agent Advances Safer Patient Care
13 juin 2022 10h00 HE | Reveal Pharmaceuticals
CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Contrast agents used in MRI scans to improve the clarity of imaging for diagnostic accuracy, accumulate in the brain and body of every patient,...
Logo.png
Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
01 juin 2022 08h00 HE | Cocrystal Pharma, Inc.
BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National...
InherentBio Logo
Inherent Biosciences, Inc. Awarded NIH SBIR Phase I Grant to Commercialize Innovative Diagnosis of Non-Obstructive Azoospermia (The Most Severe Form of Sperm Dysfunction)
13 avr. 2022 09h11 HE | Inherent Biosciences Inc
SALT LAKE CITY, April 13, 2022 (GLOBE NEWSWIRE) -- Inherent Biosciences, a biotechnology company pioneering epigenetic medicine, today announced an award from the National Institute of Child Health...
Graham headshot cropped
Co-developer of COVID-19 Vaccine Joins GreenLight Advisory Board
29 mars 2022 13h04 HE | GreenLight Biosciences
BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC, a biotechnology company focused on RNA research, product design, development, and manufacturing for human, animal, and plant...
SAB_Logo.png
SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations
02 mars 2022 06h00 HE | SAB Biotherapeutics, Inc.
NIH is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design statistically unworkable SAB-185 had advanced...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022
24 janv. 2022 15h52 HE | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases...